Switch-control KIT/PDGFRA tyrosine-kinase inhibitor

Ripretinib (Specialist drug)

Brand names: Qinlock

Ripretinib is an oral switch-control kinase inhibitor used as a specialist treatment for advanced gastrointestinal stromal tumour after prior therapies.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It broadly inhibits KIT and PDGFRA kinase signalling, including a wide range of resistance mutations, by binding the kinase switch pocket and activation loop.

Prescribing in practice

Palmar-plantar erythrodysaesthesia (hand-foot skin reaction) and other skin toxicities, including new cutaneous malignancies, occur and warrant regular skin assessment.
Hypertension and reduced cardiac function (left ventricular dysfunction) can occur and require monitoring.
Initiation is restricted to specialist oncology services experienced in kinase inhibitor toxicity.

Monitoring

Monitor blood pressure, cardiac (left ventricular) function and the skin regularly during treatment.

Counselling the patient

Report painful or blistering skin on the hands or feet and any new or changing skin lesions.
Tell the team about breathlessness, swollen ankles or new fatigue.
Attend for regular blood pressure and follow-up checks.

Evidence & guidelines

Use is supported by the INVICTUS phase III trial and the product SPC in advanced GIST.

Reference: NICE TA790; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways